Fig 1: Overall survival analysis in triple-negative breast cancer. APC, adenomatous polyposis coli protein; CCND1; cyclin D; DVL3, dishevelled segment polarity protein 3; FZD4, frizzled family receptor 4; GSK3B, glycogen synthase kinase-3 beta; LEF1, lymphoid enhancer binding factor 1; TCF7L1/2, transcription factor 7 like 1/2; WNT5 A, Wnt family member 5 A.
Fig 2: Overall survival analysis in non-luminal HER2-positive cancer. APC, adenomatous polyposis coli protein; CCND1; cyclin D; DVL3, dishevelled segment polarity protein 3; FZD4, frizzled family receptor 4; GSK3B, glycogen synthase kinase-3 beta; LEF1, lymphoid enhancer binding factor 1; TCF7L1/2, transcription factor 7 like 1/2; WNT5 A, Wnt family member 5 A.
Fig 3: Overall survival analysis in HER2-negative luminal B cancer. APC, adenomatous polyposis coli protein; CCND1; cyclin D; DVL3, dishevelled segment polarity protein 3; FZD4, frizzled family receptor 4; GSK3B, glycogen synthase kinase-3 beta; LEF1, lymphoid enhancer binding factor 1; TCF7L1/2, transcription factor 7 like 1/2; WNT5 A, Wnt family member 5 A.
Fig 4: Overall survival analysis in HER2-positive luminal B cancer. APC, adenomatous polyposis coli protein; CCND1; cyclin D; DVL3, dishevelled segment polarity protein 3; FZD4, frizzled family receptor 4; GSK3B, glycogen synthase kinase-3 beta; LEF1, lymphoid enhancer binding factor 1; TCF7L1/2, transcription factor 7 like 1/2; WNT5 A, Wnt family member 5 A.
Fig 5: Overall survival analysis in luminal A cancer. APC, adenomatous polyposis coli protein; CCND1; cyclin D; DVL3, dishevelled segment polarity protein 3; FZD4, frizzled family receptor 4; GSK3B, glycogen synthase kinase-3 beta; LEF1, lymphoid enhancer binding factor 1; TCF7L1/2, transcription factor 7 like 1/2; WNT5 A, Wnt family member 5 A.
Supplier Page from MyBioSource.com for Human Cyclin D ELISA Kit